MYGN Stock Might Gain From the New Recognition of RiskScore Study

Zacks2024-12-20

Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492607441?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-12-20 20:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492607441","market":"us","top_or_hot":-1,"title":"MYGN Stock Might Gain From the New Recognition of RiskScore Study","media":"Zacks","content":"<div>\n<p>Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mygn-stock-might-gain-recognition-125300369.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MYGN Stock Might Gain From the New Recognition of RiskScore Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMYGN Stock Might Gain From the New Recognition of RiskScore Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mygn-stock-might-gain-recognition-125300369.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mygn-stock-might-gain-recognition-125300369.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEN","symbol_name":"Penumbra Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/mygn-stock-might-gain-recognition-125300369.html","article_id":"2492607441","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492607441","pubTimestamp":1734699180,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.The all-in-one MyRisk with RiskScore test evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased risk for 11 different cancers. According to the company, the latest development underscores the clinical significance of the validation research from the study and the predictive accuracy of RiskScore.After the announcement yesterday, Myriad Genetic shares edged up 0.8% in the after-hours trading. With MyRisk expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations, we expect the latest news to positively boost the market sentiment toward MYGN stock.Earlier this month, the company announc","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEN":"Penumbra Inc","PAHC":"Phibro Animal Health Corporation","BK4007":"制药","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","HAE":"美国血液技术","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4139":"生物科技","PRS":"Prudential Financial, Inc.","MYGN":"万基遗传","BK4198":"医疗保健用品"},"translate_title":"MYGN股票可能会受益于RiskScore研究的新认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRS":1,"PEN":1,"PAHC":1,"MYGN":1,"HAE":0.9},"content_text":"Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.\nThe all-in-one MyRisk with RiskScore test evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased risk for 11 different cancers. According to the company, the latest development underscores the clinical significance of the validation research from the study and the predictive accuracy of RiskScore.\nMYGN Stock’s Likely Trend Following the News\nAfter the announcement yesterday, Myriad Genetic shares edged up 0.8% in the after-hours trading. With MyRisk expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations, we expect the latest news to positively boost the market sentiment toward MYGN stock.\nMyriad Genetics has a market capitalization of $1.21 billion. The Zacks Consensus Estimate projects the company’s 2024 earnings to increase by 144.4%. It delivered an average earnings beat of 247.73% in the trailing four quarters.  \nMore on MYGN’s RiskScore Study\nThe study by Mabey et al., “Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors,” presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing. RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model. The study demonstrated that Myriad’s PRS is a more accurate predictor of breast cancer risk than Tyrer-Cuzick alone. RiskScore delivered two times the ability to predict breast cancer risk than the Tyrer-Cuzick model.\nImage Source: Zacks Investment Research\nMyriad Genetics was one of the first commercial laboratories to market with a multi-ancestry breast cancer PRS, driven by its mission to advance health equity and deliver more inclusive genetic insights. Expressing gratitude for the recognition, the Chief Scientific Officer at MYGN stated that the selection of their paper as a major advance will continue to drive the adoption of RiskScore by providers and guideline societies.\nIndustry Prospects Favoring MYGN\nPer a research report, the global hereditary cancer testing market was valued at $3.5 billion in 2021 and is expected to grow at a compound annual rate of 11.6% through 2031. The increasing geriatric population, a surge in the incidence of cancer worldwide and an increase in the government expenditure on healthcare are some of the main factors fueling the market’s growth.\nOther Developments in Myriad Genetics\nEarlier this month, the company announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network (“NCCN”) as an ‘Advanced Tool’ in the fight against prostate cancer. For many years, Prolaris has been included in NCCN guidelines with a category 2A level of evidence, which indicates that inclusion has support from at least 85% of members on the NCCN prostate panel.\nMYGN Stock Price Performance\nIn the past month, MYGN shares have declined 12.9% compared with the industry’s fall of 3.3%.\nMYGN’s Zacks Rank and Key Picks\nMyriad Genetics currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nPenumbra shares have dropped 5.8% in the past year. Estimates for the company’s 2024 earnings per share have increased 2 cents to $2.81 in the past 30 days. PEN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.\nEstimates for Haemonetics’ fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 10.1% in the past year against the industry’s growth of 9.8%. HAE’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.\nEstimates for Phibro Animal Health’s fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 91.5% in the past year compared with the industry’s 9.8% rise. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHaemonetics Corporation (HAE) : Free Stock Analysis Report\nMyriad Genetics, Inc. (MYGN) : Free Stock Analysis Report\nPhibro Animal Health Corporation (PAHC) : Free Stock Analysis Report\nPenumbra, Inc. (PEN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492607441"}